Impax Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Impax Laboratories Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5329
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous system (CNS) disorders and other select specialties. Impax develops several controlled-release delivery technologies which can be utilized with a variety of oral dosage forms and drugs. It has manufacturing facilities in Hayward, California; Middlesex, New Jersey; and in Taiwan. The company sells its products directly to wholesalers and large retail drug chains and through unrelated third-party pharmaceutical entities. Impax is headquartered in Hayward, California, the US.

Impax Laboratories Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 13
Impax Labs Acquires Two Generic Products from Actavis 15
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 16
Partnerships 17
Impax Labs Enters Into Co-Development Agreement With Perrigo 17
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 18
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 19
Merger 20
Amneal Merges with Impax 20
Licensing Agreements 22
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 22
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 24
Debt Offering 26
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 26
Asset Transactions 28
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 29
Bora Pharma to Acquire Manufacturing Facility from Impax Labs for USD18.5 Million 31
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 32
Acquisition 33
Impax Laboratories Sells CorePharma to Group Investors 33
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 34
Impax Laboratories Inc – Key Competitors 36
Impax Laboratories Inc – Key Employees 37
Impax Laboratories Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Financial Announcements 40
Mar 01, 2018: Impax Reports Fourth Quarter and Full Year 2017 Results 40
Nov 09, 2017: Impax Reports Third Quarter 2017 Results 43
Aug 09, 2017: Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million 45
May 10, 2017: Impax Reports First Quarter 2017 Financial Results 47
Mar 01, 2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results 50
Corporate Communications 53
Nov 08, 2017: Impax Laboratories Mourns the Passing of Board Member Richard A. Bierly 53
Mar 27, 2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 13
Impax Labs Acquires Two Generic Products from Actavis 15
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 16
Impax Labs Enters Into Co-Development Agreement With Perrigo 17
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 18
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 19
Amneal Merges with Impax 20
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 22
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 24
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 26
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 29
Bora Pharma to Acquire Manufacturing Facility from Impax Labs for USD18.5 Million 31
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 32
Impax Laboratories Sells CorePharma to Group Investors 33
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 34
Impax Laboratories Inc, Key Competitors 36
Impax Laboratories Inc, Key Employees 37
Impax Laboratories Inc, Other Locations 38
Impax Laboratories Inc, Subsidiaries 38

List of Figures
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Impax Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vinci Construction UK Ltd:企業の戦略・SWOT・財務情報
    Vinci Construction UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Vinci Construction UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AiCuris GmbH & Co KG-製薬・医療分野:企業M&A・提携分析
    Summary AiCuris GmbH & Co KG (AiCuris), a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents …
  • Alphabet Inc:企業のM&A・事業提携・投資動向
    Alphabet Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alphabet Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Japan Airlines Co Ltd
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sumitomo Electric Industries Ltd (5802)-エネルギー分野:企業M&A・提携分析
    Summary Sumitomo Electric Industries, Ltd. (Sumitomo) is a manufacturing company that develops, manufactures, and sells various products related to electronics, infocommunications, automotive, industrial materials, and environment and energy. The company’s product portfolio includes wiring harnesses …
  • BIM Birlesik Magazalar A.S.:戦略・SWOT・企業財務分析
    BIM Birlesik Magazalar A.S. - Strategy, SWOT and Corporate Finance Report Summary BIM Birlesik Magazalar A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • CardioFocus Inc:医療機器:M&Aディール及び事業提携情報
    Summary CardioFocus Inc (CardioFocus) is a medical device company that manufactures and distributes endoscopic ablation system for the treatment of cardiac disorders. The company offers heartlight endoscopic ablation system, which includes balloon catheter, endoscope, deflectable sheath, and integra …
  • CalciMedica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CalciMedica Inc (CalciMedica) is a pharmaceutical company that develops small molecule drugs for the treatment of acute and chronic inflammatory and autoimmune disorders and organ transplant rejection. The company’s CM2489 is a compound developed to treat moderate plaque psoriasis. It also i …
  • The Chiba Bank Ltd:企業の戦略・SWOT・財務情報
    The Chiba Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Chiba Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kuros Biosciences AG (KURN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as we …
  • Digital China Holdings Limited:企業の戦略・SWOT・財務情報
    Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Mayo Foundation for Medical Education and Research:企業の戦略的SWOT分析
    Mayo Foundation for Medical Education and Research - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compet …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Albemarle Corporation:企業の戦略・SWOT・財務情報
    Albemarle Corporation - Strategy, SWOT and Corporate Finance Report Summary Albemarle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sun Pharma Advanced Research Company Ltd (SPARC)-製薬・医療分野:企業M&A・提携分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd is a pharma research and drug discovery company that conducts research and and produces drugs. The company develops active pharmaceutical ingredients, formulations and drug delivery technologi …
  • Claret Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Claret Medical Inc (Claret Medical), a subsidiary of Boston Scientific Corp develops and commercializes cerebral protection systems. The company offers medical devices for cerebral protection during structural heart and vascular interventions, and cardiac surgery procedures. Its lead product …
  • LHC Group, Inc.:企業のM&A・事業提携・投資動向
    LHC Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LHC Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Aliancys AG:企業の戦略的SWOT分析
    Aliancys AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Synexus Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Synexus Ltd (Synexus), a subsidiary of Synexus Clinical Research Limited, is a site management organisation that offers patient recruitment and trial management services. The company services include feasibility assessment, project management, patient engagement, patient-centric clinical tri …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆